Gentherm Inc (THRM) Stock Analysis and Metrics

Gentherm

NASDAQ: THRM

$36.12 ▲ +0.29 (+0.81%)

At close: Jul 13, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap221.52 Mn

P/E2.12

P/S0.14

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)219.04 Mn

Revenue Growth (1y) (Qtr)11.26

Add ratio to table…

About

Gentherm Incorporated is a global market leader of innovative thermal management and pneumatic comfort technologies. The company designs, develops, manufactures and sells products for the automotive and medical industries. Revenue is generated primarily from the sale of automotive climate and comfort solutions valve systems and other automotive products as well as patient temperature management systems. The company sells its products to original equipment manufacturers tier…

Investment Thesis

▲ Bull case

Gentherm is executing a strategic realignment that segments operations by product into Climate Comfort, Valves, and Medical business units, which is expected to deliver approximately $10 million in annualized OpEx run-rate benefits, with half realized in 2026. This structural change reduces organizational complexity, accelerates decision-making, and focuses resources on high-growth platforms outside traditional automotive markets. By eliminating redundant layers and aligning functions around product lines rather than geography, the company is positioning itself to scale innovation more efficiently in adjacent markets like home, office, and medical, where sales cycles are shorter and customer acquisition costs are lower. The realignment also supports the integration of Modine Performance Technologies by creating a leaner corporate overhead structure, allowing combined entity synergies to flow through to the bottom line faster than anticipated. This operational rigor, already visible in Q1 FY26 with adjusted EBITDA margin expansion to 12.5% from 11.1% year-over-year, is laying the foundation for sustained margin improvement as inflationary cost pressures are gradually recovered through commercial negotiations.
The company’s expansion into the home and office market is gaining tangible traction, having secured production with KUKA Home and a new North American furniture customer in Q1 FY26—marking four consecutive quarters of new customer wins in this segment. Management projects this market could contribute between $50 million and $100 million in annual revenue by 2028, representing accretive growth at margins comparable to or better than core automotive businesses. Unlike the volatile and cyclical light vehicle sector, home and office demand is more stable, driven by secular trends in comfort-focused living and working environments, with shorter design-to-revenue cycles enabled by Gentherm’s standard kit methodology. Early partnerships are validating the scalability of its thermal comfort technology beyond vehicles, reducing reliance on OEM programming cycles and opening doors to direct-to-consumer or contract manufacturer models. This diversification not only reduces automotive concentration risk but also provides a counterbalancing revenue stream that could sustain growth even if light vehicle production faces headwinds from EV transition delays or regional economic softness.
Gentherm’s medical segment is advancing with the FDA 510(k) submission for ThermAffyx, a novel conductive air-free patient warming and securement system designed for robotic surgery procedures. If approved, this product addresses a growing clinical need to prevent hypothermia and unintended patient movement during minimally invasive surgeries—a market expanding rapidly with the global adoption of robotic-assisted systems. Management expects revenue generation to begin later in 2026 pending regulatory clearance, positioning ThermAffyx as a potential early contributor to medical segment growth. The product leverages Gentherm’s core expertise in precision thermal management while creating defensible differentiation through integrated securement technology, which could command premium pricing and reduce competitive pressure. Success here would validate the company’s ability to innovate in regulated, high-barrier markets and open pathways for follow-on indications in areas like patient transport, imaging, or long-term care. With the medical device outsourcing market projected to grow at a mid-single-digit CAGR, Gentherm’s early-mover advantage in this niche could yield outsized returns relative to investment.
The pending merger with Modine Performance Technologies remains on track for closing later in 2026, having already secured HSR clearance—a significant regulatory de-risking milestone. Management envisions the combined entity achieving $3.5 billion in revenue and over $0.5 billion in earnings within five years, driven by expanded end-market exposure into power generation, commercial vehicles, and heavy-duty equipment. Modine brings complementary strengths in thermal and precision flow management, enabling cross-selling opportunities and integrated solutions that Gentherm alone could not offer. The integration strategy focuses on aligning corporate systems and functional support rather than complex operational consolidation, minimizing disruption and accelerating synergy capture. With net leverage at just 0.2 turns and $456 million in liquidity, Gentherm has ample financial flexibility to fund integration costs without straining the balance sheet. The combined company’s diversified industrial footprint would reduce reliance on cyclical automotive demand and create a more resilient platform for long-term value creation, especially as infrastructure spending and electrification of non-auto sectors accelerate.
Despite near-term margin pressure from inflationary cost headwinds, Gentherm demonstrated strong operational execution in Q1 FY26, delivering a quarterly revenue record of $394 million—up 11.3% year-over-year—and adjusted EPS of $0.84, up 65% from $0.51 a year ago. This performance was driven by broad-based growth across regions and products, particularly in Automotive Climate and Comfort Solutions, which grew 13.6% year-over-year (9.8% ex-FX) due to new program launches in China and increased take rates from both domestic and global OEMs. Lumbar and massage comfort solutions continued their momentum with 33% year-over-year growth, reflecting successful ramp of previously won business. The company also improved cash flow by $8 million year-over-year and reduced CapEx by $9.2 million, signaling disciplined capital allocation. These results indicate that Gentherm’s operational excellence initiatives are taking hold, and the underlying business is more resilient than headline guidance suggests. With management maintaining full-year revenue guidance of $1.5–$1.6 billion (3% growth) and reaffirming confidence in mid-single-digit outperformance versus light vehicle production, the stock may be undervalued if investors are overemphasizing temporary Q2–Q3 margin volatility while overlooking the durability of organic growth drivers and the long-term value of diversification and merger synergies.

Gentherm is executing a strategic realignment that segments operations by product into Climate Comfort, Valves, and Medical business units, which is expected to deliver approximately $10 million in annualized OpEx run-rate benefits, with half realized in 2026. This structural change reduces organizational complexity, accelerates decision-making, and focuses resources on high-growth platforms outside traditional automotive markets. By eliminating redundant layers and aligning functions around product lines rather than geography, the company is positioning itself to scale innovation more efficiently in adjacent markets like home, office, and medical, where sales cycles are shorter and customer acquisition costs are lower. The realignment also supports the integration of Modine Performance Technologies by creating a leaner corporate overhead structure, allowing combined entity synergies to flow through to the bottom line faster than anticipated. This operational rigor, already visible in Q1 FY26 with adjusted EBITDA margin expansion to 12.5% from 11.1% year-over-year, is laying the foundation for sustained margin improvement as inflationary cost pressures are gradually recovered through commercial negotiations.
The company’s expansion into the home and office market is gaining tangible traction, having secured production with KUKA Home and a new North American furniture customer in Q1 FY26—marking four consecutive quarters of new customer wins in this segment. Management projects this market could contribute between $50 million and $100 million in annual revenue by 2028, representing accretive growth at margins comparable to or better than core automotive businesses. Unlike the volatile and cyclical light vehicle sector, home and office demand is more stable, driven by secular trends in comfort-focused living and working environments, with shorter design-to-revenue cycles enabled by Gentherm’s standard kit methodology. Early partnerships are validating the scalability of its thermal comfort technology beyond vehicles, reducing reliance on OEM programming cycles and opening doors to direct-to-consumer or contract manufacturer models. This diversification not only reduces automotive concentration risk but also provides a counterbalancing revenue stream that could sustain growth even if light vehicle production faces headwinds from EV transition delays or regional economic softness.
Gentherm’s medical segment is advancing with the FDA 510(k) submission for ThermAffyx, a novel conductive air-free patient warming and securement system designed for robotic surgery procedures. If approved, this product addresses a growing clinical need to prevent hypothermia and unintended patient movement during minimally invasive surgeries—a market expanding rapidly with the global adoption of robotic-assisted systems. Management expects revenue generation to begin later in 2026 pending regulatory clearance, positioning ThermAffyx as a potential early contributor to medical segment growth. The product leverages Gentherm’s core expertise in precision thermal management while creating defensible differentiation through integrated securement technology, which could command premium pricing and reduce competitive pressure. Success here would validate the company’s ability to innovate in regulated, high-barrier markets and open pathways for follow-on indications in areas like patient transport, imaging, or long-term care. With the medical device outsourcing market projected to grow at a mid-single-digit CAGR, Gentherm’s early-mover advantage in this niche could yield outsized returns relative to investment.
The pending merger with Modine Performance Technologies remains on track for closing later in 2026, having already secured HSR clearance—a significant regulatory de-risking milestone. Management envisions the combined entity achieving $3.5 billion in revenue and over $0.5 billion in earnings within five years, driven by expanded end-market exposure into power generation, commercial vehicles, and heavy-duty equipment. Modine brings complementary strengths in thermal and precision flow management, enabling cross-selling opportunities and integrated solutions that Gentherm alone could not offer. The integration strategy focuses on aligning corporate systems and functional support rather than complex operational consolidation, minimizing disruption and accelerating synergy capture. With net leverage at just 0.2 turns and $456 million in liquidity, Gentherm has ample financial flexibility to fund integration costs without straining the balance sheet. The combined company’s diversified industrial footprint would reduce reliance on cyclical automotive demand and create a more resilient platform for long-term value creation, especially as infrastructure spending and electrification of non-auto sectors accelerate.
Despite near-term margin pressure from inflationary cost headwinds, Gentherm demonstrated strong operational execution in Q1 FY26, delivering a quarterly revenue record of $394 million—up 11.3% year-over-year—and adjusted EPS of $0.84, up 65% from $0.51 a year ago. This performance was driven by broad-based growth across regions and products, particularly in Automotive Climate and Comfort Solutions, which grew 13.6% year-over-year (9.8% ex-FX) due to new program launches in China and increased take rates from both domestic and global OEMs. Lumbar and massage comfort solutions continued their momentum with 33% year-over-year growth, reflecting successful ramp of previously won business. The company also improved cash flow by $8 million year-over-year and reduced CapEx by $9.2 million, signaling disciplined capital allocation. These results indicate that Gentherm’s operational excellence initiatives are taking hold, and the underlying business is more resilient than headline guidance suggests. With management maintaining full-year revenue guidance of $1.5–$1.6 billion (3% growth) and reaffirming confidence in mid-single-digit outperformance versus light vehicle production, the stock may be undervalued if investors are overemphasizing temporary Q2–Q3 margin volatility while overlooking the durability of organic growth drivers and the long-term value of diversification and merger synergies.

▼ Bear case

Gentherm faces significant near-term margin pressure due to timing mismatches between the realization of approximately $20 million in annualized inflationary cost increases and their recovery from customers, with management explicitly expecting margins to be depressed in Q2 and Q3 FY26. These costs—driven by freight (roughly one-third), petrochemical/commodity inputs, and incremental processing expenses—lack contractual escalators, requiring active renegotiation with customers who may resist price increases amid their own margin pressures. The company anticipates a delay in recovery, with costs hitting in Q2 and recovery mechanisms only beginning to flow in Q3–Q4, creating a prolonged period of gross margin erosion. This is compounded by the deliberate depletion of inventory banks as the global footprint transition concludes, which will further weigh on gross margins in the coming quarters. Unlike temporary supply chain shocks, these cost pressures appear structural and persistent, tied to ongoing geopolitical disruptions and energy market volatility, with no guarantee of successful pass-through. If negotiations falter or customers delay agreements, the impact could extend beyond the guided timeframe, undermining profitability forecasts and forcing deeper operational cuts that may hinder growth investments.
Although Gentherm highlights new wins in the home and office market—including production launch with KUKA Home and a new North American furniture customer—the scalability and profitability of this expansion remain unproven at scale. The company projects only $50–$100 million in annual revenue from this segment by 2028, which, even at the high end, represents less than 7% of the guided $1.5–$1.6 billion FY26 revenue base. Early successes may reflect low-hanging fruit from partnership-driven co-branding rather than broad market adoption, and there is limited evidence of pricing power or repeatability across diverse furniture manufacturers. The reliance on standard kit methodology minimizes upfront investment but may also cap differentiation and long-term margins if competitors replicate the approach. Furthermore, home and office demand is susceptible to discretionary spending cycles, which could weaken during broader economic downturns—precisely when Gentherm may need non-automotive revenue most. Without clear data on customer concentration, attachment rates, or margin profiles in this segment, investors cannot confidently assume this diversification will meaningfully derisk the business or deliver accretive growth in the near to medium term.
The medical segment’s growth hinges on the regulatory approval of ThermAffyx, whose FDA 510(k) submission remains pending with no guaranteed timeline for clearance. Even if approved, the product addresses a niche within the robotic surgery ecosystem—patient warming and securement during inclined procedures—whose total addressable market size and adoption rate are uncertain. Success requires not only regulatory clearance but also clinical validation, hospital buy-in, and reimbursement pathway establishment, all of which could take longer than management’s optimistic “later in 2026” revenue expectation. There is also risk that competitors with established presence in OR ecosystems (e.g., Stryker, Medtronic) could rapidly develop or acquire equivalent technologies, limiting Gentherm’s first-mover advantage. Given the medical segment’s current contribution to overall revenue is minimal, any delay or failure in ThermAffyx commercialization would represent a significant opportunity cost and could call into question the efficacy of the company’s diversification strategy. Until the product demonstrates traction in real-world clinical settings, its potential remains speculative and should not be relied upon as a near-term growth catalyst.
The proposed merger with Modine Performance Technologies, while having cleared HSR review, still faces execution risks that could delay or diminish the anticipated synergies. Integration efforts are focused on aligning corporate systems and functional support, but cultural alignment, IT system compatibility, and redundant role resolution could prove more complex and costly than anticipated, especially given the combined entity’s ambition to operate Modine as a stand-alone division. Management targets a $10 million OpEx run-rate benefit from Gentherm’s internal realignment, but achieving similar efficiencies in the merged entity will require significant change management and may distract from core operations. Furthermore, the five-year target of $3.5 billion in revenue and over $0.5 billion in earnings assumes successful cross-selling into power generation, commercial vehicles, and heavy-duty equipment—markets where Gentherm has limited historical presence and where Modine’s strengths may not fully translate. If integration delays occur or expected synergies fail to materialize, the deal could become a financial burden rather than a value creator, particularly if leverage increases unexpectedly or expected cost savings are offset by integration expenses. With closing still targeted for later in 2026, any macroeconomic deterioration or regulatory setback could jeopardize the transaction timeline.
Gentherm’s full-year guidance of $1.5–$1.6 billion in revenue (3% growth) and $175–$195 million in adjusted EBITDA appears increasingly optimistic given the explicit warning of margin depression in Q2 and Q3 due to unrecovered inflationary costs and inventory bank depletion. The company expects to mitigate only a “meaningful portion” of the $20 million in annualized cost increases through commercial and operational initiatives, leaving a significant gap that could weigh heavily on profitability. At the same time, light vehicle production—the core of Gentherm’s business—is projected to decline approximately 2% for the year per industry reports, yet Gentherm guides to only mid-single-digit outperformance, implying a sharp deceleration from Q1’s 11.3% year-over-year growth. This slowdown suggests that the strong start was driven by transient factors such as regional OEM program ramp-ups or temporary take-rate increases, not sustainable structural advantage. If automotive outperformance fades more quickly than anticipated and diversification efforts fail to compensate, the company could struggle to meet guidance, leading to downward revisions and multiple compression. With GAAP earnings already heavily impacted by merger-related expenses ($0.70 per share in Q1), any further disappointment in adjusted results would amplify investor concerns about the quality of earnings and the durability of the turnaround narrative.

Gentherm faces significant near-term margin pressure due to timing mismatches between the realization of approximately $20 million in annualized inflationary cost increases and their recovery from customers, with management explicitly expecting margins to be depressed in Q2 and Q3 FY26. These costs—driven by freight (roughly one-third), petrochemical/commodity inputs, and incremental processing expenses—lack contractual escalators, requiring active renegotiation with customers who may resist price increases amid their own margin pressures. The company anticipates a delay in recovery, with costs hitting in Q2 and recovery mechanisms only beginning to flow in Q3–Q4, creating a prolonged period of gross margin erosion. This is compounded by the deliberate depletion of inventory banks as the global footprint transition concludes, which will further weigh on gross margins in the coming quarters. Unlike temporary supply chain shocks, these cost pressures appear structural and persistent, tied to ongoing geopolitical disruptions and energy market volatility, with no guarantee of successful pass-through. If negotiations falter or customers delay agreements, the impact could extend beyond the guided timeframe, undermining profitability forecasts and forcing deeper operational cuts that may hinder growth investments.
Although Gentherm highlights new wins in the home and office market—including production launch with KUKA Home and a new North American furniture customer—the scalability and profitability of this expansion remain unproven at scale. The company projects only $50–$100 million in annual revenue from this segment by 2028, which, even at the high end, represents less than 7% of the guided $1.5–$1.6 billion FY26 revenue base. Early successes may reflect low-hanging fruit from partnership-driven co-branding rather than broad market adoption, and there is limited evidence of pricing power or repeatability across diverse furniture manufacturers. The reliance on standard kit methodology minimizes upfront investment but may also cap differentiation and long-term margins if competitors replicate the approach. Furthermore, home and office demand is susceptible to discretionary spending cycles, which could weaken during broader economic downturns—precisely when Gentherm may need non-automotive revenue most. Without clear data on customer concentration, attachment rates, or margin profiles in this segment, investors cannot confidently assume this diversification will meaningfully derisk the business or deliver accretive growth in the near to medium term.
The medical segment’s growth hinges on the regulatory approval of ThermAffyx, whose FDA 510(k) submission remains pending with no guaranteed timeline for clearance. Even if approved, the product addresses a niche within the robotic surgery ecosystem—patient warming and securement during inclined procedures—whose total addressable market size and adoption rate are uncertain. Success requires not only regulatory clearance but also clinical validation, hospital buy-in, and reimbursement pathway establishment, all of which could take longer than management’s optimistic “later in 2026” revenue expectation. There is also risk that competitors with established presence in OR ecosystems (e.g., Stryker, Medtronic) could rapidly develop or acquire equivalent technologies, limiting Gentherm’s first-mover advantage. Given the medical segment’s current contribution to overall revenue is minimal, any delay or failure in ThermAffyx commercialization would represent a significant opportunity cost and could call into question the efficacy of the company’s diversification strategy. Until the product demonstrates traction in real-world clinical settings, its potential remains speculative and should not be relied upon as a near-term growth catalyst.
The proposed merger with Modine Performance Technologies, while having cleared HSR review, still faces execution risks that could delay or diminish the anticipated synergies. Integration efforts are focused on aligning corporate systems and functional support, but cultural alignment, IT system compatibility, and redundant role resolution could prove more complex and costly than anticipated, especially given the combined entity’s ambition to operate Modine as a stand-alone division. Management targets a $10 million OpEx run-rate benefit from Gentherm’s internal realignment, but achieving similar efficiencies in the merged entity will require significant change management and may distract from core operations. Furthermore, the five-year target of $3.5 billion in revenue and over $0.5 billion in earnings assumes successful cross-selling into power generation, commercial vehicles, and heavy-duty equipment—markets where Gentherm has limited historical presence and where Modine’s strengths may not fully translate. If integration delays occur or expected synergies fail to materialize, the deal could become a financial burden rather than a value creator, particularly if leverage increases unexpectedly or expected cost savings are offset by integration expenses. With closing still targeted for later in 2026, any macroeconomic deterioration or regulatory setback could jeopardize the transaction timeline.
Gentherm’s full-year guidance of $1.5–$1.6 billion in revenue (3% growth) and $175–$195 million in adjusted EBITDA appears increasingly optimistic given the explicit warning of margin depression in Q2 and Q3 due to unrecovered inflationary costs and inventory bank depletion. The company expects to mitigate only a “meaningful portion” of the $20 million in annualized cost increases through commercial and operational initiatives, leaving a significant gap that could weigh heavily on profitability. At the same time, light vehicle production—the core of Gentherm’s business—is projected to decline approximately 2% for the year per industry reports, yet Gentherm guides to only mid-single-digit outperformance, implying a sharp deceleration from Q1’s 11.3% year-over-year growth. This slowdown suggests that the strong start was driven by transient factors such as regional OEM program ramp-ups or temporary take-rate increases, not sustainable structural advantage. If automotive outperformance fades more quickly than anticipated and diversification efforts fail to compensate, the company could struggle to meet guidance, leading to downward revisions and multiple compression. With GAAP earnings already heavily impacted by merger-related expenses ($0.70 per share in Q1), any further disappointment in adjusted results would amplify investor concerns about the quality of earnings and the durability of the turnaround narrative.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Auto Parts

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AAP	Advance Auto Parts Inc	65.13 Bn	-2,713.78	7.57	3.41 Bn
2	AZO	Autozone Inc	53.07 Bn	28.80	2.66	9.02 Bn
3	MGA	Magna International Inc	17.54 Bn	44.62	0.56	4.66 Bn
4	GPC	Genuine Parts Co	16.15 Bn	268.82	0.65	4.64 Bn
5	AUR	Aurora Innovation, Inc.	13.77 Bn	-16.57	3,443.09	-
6	BWA	Borgwarner Inc	13.21 Bn	51.79	0.92	3.88 Bn
7	APTV	Aptiv PLC	12.84 Bn	-40.37	0.62	9.35 Bn
8	ALV	Autoliv Inc	8.73 Bn	-72.12	0.79	2.09 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password